Baclofen

Baclofen, originally created as a gamma-aminobutyric acid-B (GABA-B) receptor agonist to treat muscle spasticity, has garnered significant interest as a treatment for alcohol use disorder (AUD). Research first suggested its potential in reducing alcohol cravings in early studies, and its effectiveness was confirmed in clinical trials beginning in 2000. This sparked broader scientific exploration into baclofen’s role in supporting abstinence among AUD patients. Baclofen’s efficacy in treating AUD has been examined through various randomized controlled trials (RCTs) and observational studies, though results have been mixed; while RCTs show variable outcomes, observational studies consistently highlight its benefits. In France, baclofen has gained widespread use as an approved AUD treatment, with physicians personalizing doses to suit patient needs. This approach allows dosage flexibility, with patients receiving between 30 to 300 mg/day depending on the severity of their cravings. Tailored dosing is especially beneficial in managing long-term recovery.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.